Tempest Therapeutics (TPST) Interest Expenses (2011 - 2025)
Tempest Therapeutics (TPST) posted Interest Expenses of $10.8 million for Q3 2025, up 315.51% sequentially from $2.6 million in Q2 2025, and up 3181.16% YoY from $329000.0 in Q3 2024.
Tempest Therapeutics (TPST) Interest Expenses (2011 - 2025) Analysis & Trends
Tempest Therapeutics has reported Interest Expenses for 15 years, with the latest figure at $10.8 million in Q3 2025.
- Quarterly Interest Expenses rose 3181.16% year-over-year to $10.8 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $713000.0 (down 44.81% YoY) and the FY2025 annual result came in at $2.2 million, down 98.75% from the prior year.
- Interest Expenses rose to $10.8 million in Q3 2025 per TPST's latest filing, from $2.6 million in the prior quarter.
- Over five years, Interest Expenses peaked at $10.8 million in Q3 2025 and troughed at $161000.0 in Q1 2025.
- A 5-year average of $1.1 million and a median of $372000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2025: Interest Expenses plunged 94.14% in 2021, then soared 3181.16% in 2025.
- Over 5 years, Interest Expenses stood at $338000.0 in 2021, then climbed by 27.81% to $432000.0 in 2022, then declined by 12.73% to $377000.0 in 2023, then plunged by 40.85% to $223000.0 in 2024, then jumped by 4740.81% to $10.8 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $10.8 million, $2.6 million, and $161000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 93.62 Mn |
| 10 | Tempest Therapeutics | 4.46 Mn | 3.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 10.80 Mn |
| Sep 30, 2025 | 10.80 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Mar 31, 2024 | 368,000.00 |
| Mar 31, 2024 | 368,000.00 |
| Dec 31, 2023 | 377,000.00 |
| Dec 31, 2023 | 377,000.00 |
| Sep 30, 2023 | 373,000.00 |
| Sep 30, 2023 | 373,000.00 |